In addition, another clinical trial is being conducted to test the safety, tolerability and pharmacodynamics of a synthetic FXR agonist EYP001a in patients with NASH and to evaluate the influence of EYP001a on bile acid metabolism (NCT03976687). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.